Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

First subjects dosed in study comparing nasal nalmefene with nasal naloxone

April 6, 2021

Primary safety endpoint met in phase Ib/II study of BXCL-501 to treat opioid withdrawal symptoms

April 1, 2021

Brain cell alcohol metabolism affects behavior, addiction

March 25, 2021

DemeRx receives approval for phase I/II study of ibogaine in the U.K.

March 11, 2021

FDA gives clearance to initiate clinical development of KP-879

Jan. 28, 2021

Neuron-specific delivery platform based on a chimeric toxin for botulism postexposure treatment

Jan. 26, 2021

New adenosine A2A receptor antagonists presented by AMMS

Jan. 13, 2021

Braeburn receives complete response letter for Brixadi in the U.S.

Dec. 3, 2020

Nirsum Laboratories presents prodrugs of opioid receptor antagonists

Dec. 1, 2020

BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice

Oct. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...